Why PSA Guidelines Are Failing Men and What Better Screening Looks Like

Prostate cancer remains one of the most preventable cancer deaths, yet advanced and metastatic diagnoses continue to climb. Peter Attia argues this is not a failure of science but a failure of guidelines — specifically, the retreat from routine PSA screening driven by overdiagnosis concerns in the early 2000s. This episode makes the case that the pendulum swung too far, and that men are now paying with their lives.

Attia begins with PSA fundamentals, explaining that a single PSA value is far less informative than PSA velocity and density tracked over time. A rising PSA trend, even within a 'normal' range, can signal aggressive disease years before symptoms appear. He walks through how MRI-guided biopsy and newer imaging advances allow clinicians to target suspicious lesions precisely, reducing both false negatives and unnecessary biopsies.

A central critique targets the PLCO trial, the landmark study most often cited to argue against PSA screening. Attia details significant methodological flaws — including widespread contamination in the control arm — that undermine its conclusions. He contrasts this with European trial data showing meaningful mortality reductions from organized screening programs.

The episode also covers Gleason scoring and active surveillance, presenting them as tools that allow low-risk cancers to be monitored rather than overtreated. For men on finasteride or dutasteride, Attia flags a critical clinical point: these drugs suppress PSA by roughly 50%, meaning standard thresholds must be adjusted or warning signs will be missed.

Finally, Attia expresses cautious optimism about the future, noting that better liquid biopsies, imaging, and risk stratification tools are converging to make prostate cancer mortality increasingly preventable. The episode is a call to action for both patients and clinicians to demand more rigorous, individualized screening rather than accepting one-size-fits-all guidelines.